Please login to the form below

Not currently logged in
Email:
Password:

Priority review for stroke drug

The US FDA has granted priority review for Boehringer Ingelheim's dabigatran etexilate for the prevention of stroke in patients with atrial fibrillation

The US Food and Drug Administration (FDA) has granted priority review for Boehringer Ingelheim's oral direct thrombin inhibitor dabigatran etexilate for the prevention of stroke in patients with atrial fibrillation (AF).

Therapies qualify for priority review if they offer major advances in treatment, or provide a treatment where no adequate therapy exists.

The decision is based on the results of the phase III RE-LY study (Randomised Evaluation of Long-term anticoagulant therapY), which compared the safety and efficacy of dabigatran etexilate with current therapy, warfarin.

These results showed dabigatran etexilate significantly reduced the risk of stroke and systemic embolism in patients with AF by 34 per cent compared to warfarin.

Boehringer's drug also had fewer side-effects than warfarin, showing a reduction in haemorrhagic stroke as well as intracranial and total bleeding.

Professor Jonas Oldgren, associate professor of cardiology, Uppsala Clinical Research Centre, one of the coordinating centres in RE-LY, said: "Dabigatran etexilate is the first treatment to significantly reduce stroke in patients with atrial fibrillation across all risk groups, when compared to well-controlled warfarin. This novel direct thrombin inhibitor could represent a very important advance in the prevention of stroke in patients with AF for both healthcare professionals and patients alike."

An advisory committee for the FDA will meet on September 20 to further review dabigatran etexilate data.

The drug is also under review by the region's respective regulatory bodies in Europe and Japan, with Boehringer expecting to receive initial marketing authorisation for dabigatran etexilate at end of 2010 or beginning of 2011.

31st August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics